Contact Us to Book
Get in touch to arrange your TruCheck cancer screening blood test.
TruCheck™ is the most effective and convenient diagnostic blood test available to distinguish up to 70 types of solid cancer tumours. New in the UK, this test is revolutionising the ability to detect cancer at its earliest stages, and Makewell is proud to be one of the first providers in the country to offer it to the British public.
When you detect cancer in its early stages, treatment can be more effective, and the chances of a positive outcome are significantly increased. It can also help prevent the spread of cancer to other parts of the body.
Ideal as part of an annual health check up, this test will help you understand whether you currently have cancer or not, and if you do – where tumours are located for rapid assessment and treatment.
TruCheck™ looks for Circulating Tumour Cells (CTC) and clusters of the cells in the blood, which malignant tumours release. These cells are the main reason cancer eventually spreads in the body. Extensive research of more than 40,000 participants shows Circulating Tumour Cells are primary evidence of cancer.
Launched in the UK in late 2022 after rigorous clinical trials, this test is brand new to the diagnostic screening industry. It is the only test available publicly to check for Circulating Tumour Cells (CTCs), detecting even the tiniest existence of cancer from a small blood sample.
Highly accurate, it not only identifies whether you have CTCs, but also where they originated. This means you know where in your body the primary tumour is located, speeding up diagnosis and treatment.
Our test can identify a wide range of solid organ cancers including:
Melanoma, Head and Neck, Salivary Gland, Thyroid, Lung, Breast, Liver, Biliary Tract, Gastrointestinal, Soft Tissue, Osteosarcomas, Mesothelioma, Urinary Tract, Gynaecological, Prostate, Thymus, Adrenal, Central Nervous System, and many more.
To take this test you must:
Please ensure you carefully review the eligibility criteria before booking, as failure to meet the criteria may result in the test being declined during pre-consultation, and a refund will be issued minus the cost of the GP’s pre-consultation.
TruCheck™ looks for Circulating Tumour Cells (CTC) and clusters of the cells in the blood, which malignant tumours release. These cells are the main reason cancer eventually spreads in the body. Extensive research of more than 40,000 participants shows Circulating Tumour Cells are primary evidence of cancer.
Contact us to book. We will arrange a pre-test consultation with a Doctor who will explain how the test works and arrange to take your blood in clinic. During the pre-consultation phone call, the Doctor will speak to you to understand your medical history and reason for the test, and discuss the risks and benefits. If you are not suitable or choose not to proceed, you will be issued a refund.
Results come back in 2-3 weeks. The Doctors will contact you with your results. With any positive test, a member of the clinical team will call you personally to discuss your results, what they mean and guide you on next steps.
A positive result means that CTCs have been found in your blood. The test results will indicate the location for the select type of cancers with high accuracy, and in other cancers the tissue of origin can be identified with reasonable accuracy. This means we can tell you where the cancer started developing in your body.
A negative result means that at the time of the test there were no detectable cancer cells for the cancers included within the test, circulating in your blood. It does not mean that you will never develop cancer. For any cancers not covered by the test, no inference should be drawn from a negative result.
As this early cancer screening test is non-invasive, there is no disadvantage to frequent testing. However, we advise that this test should be performed every 12 months in the case of each negative result, perhaps as part of an annual complete health check process.
Although both tests aim to identify early stage cancers in the blood, the technology is quite different. Grail relies on indirect detection of cells, whereas TruCheck™ uses immunocytochemistry to directly detect actual Circulating Tumour Cells (CTCs). Grail is not available in the UK as a private test and is currently only being conducted as part of an NHS Clinical trial. The supporting medical trial data for Grail has not been as strong in detecting early-stage cancers compared to TruCheck™, and so the overall cancer pick-up rate is lower.
Our team is here to answer your questions and help you take the next step.
© 2026 Makewell Health and Wellness Clinic